Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental models - Wikidata - awgldk - TriplyDB

Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental models

Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental models

http://www.wikidata.org/entity/Q34788361

about

The Fate of the Tumor in the Hands of Microenvironment: Role of TAMs and mTOR Pathway.mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.Cardamonin Inhibits Metastasis of Lewis Lung Carcinoma Cells by Decreasing mTOR Activity Evidence Supporting a Lymphatic Endothelium Origin for Angiomyolipoma, a TSC2(-) Tumor Related to Lymphangioleiomyomatosis.mTOR Inhibition: From Aging to Autism and Beyond.Rapamycin targets Interleukin 6 (IL-6) expression and suppresses endothelial cell invasion stimulated by tumor cells.Novel targeted therapies for the treatment of penile cancer.Rapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract.Gene expression profiling to predict recurrence of advanced squamous cell carcinoma of the tongue: discovery and external validation.

P2860

Q33364555-A9F91B21-4E76-456A-A6B9-467456003A38 Q34049613-32447451-33FE-42E3-B4FF-C794B5BA8F80 Q35633988-59B6C33D-0F65-472E-B305-76396F791749 Q37057152-5CC2820A-0D13-42AC-BB74-D211DB8BD630 Q37385781-0D86CBC5-918C-4396-AD3A-79E39943F21E Q37448156-F019A6F5-4079-4398-925A-5C49DCFCAA97 Q38217530-719305F3-13A0-44BE-B52F-BE77350BE103 Q41970819-477260F6-A1A5-4FFC-B888-55BBDD0D820F Q42365301-0C1A8284-A5C6-41DA-BA79-FBFA6E55F651

P2860

Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental models

http://www.wikidata.org/entity/Q34788361

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

Anti-lymphangiogenic propertie ...... carcinoma experimental models

@ast

Anti-lymphangiogenic propertie ...... carcinoma experimental models

@en

Anti-lymphangiogenic propertie ...... carcinoma experimental models

@nl

type

label

Anti-lymphangiogenic propertie ...... carcinoma experimental models

@ast

Anti-lymphangiogenic propertie ...... carcinoma experimental models

@en

Anti-lymphangiogenic propertie ...... carcinoma experimental models

@nl

prefLabel

Anti-lymphangiogenic propertie ...... carcinoma experimental models

@ast

Anti-lymphangiogenic propertie ...... carcinoma experimental models

@en

Anti-lymphangiogenic propertie ...... carcinoma experimental models

@nl

P1433

Q34788361-567E4A58-EB1C-4E6D-9965-A58949F14A0C

P1476

Q34788361-218B52CF-7DF1-4F1E-892C-2B72B705D47D

P2093

Q34788361-09DC8E5B-48EC-4C8B-AEDD-C9BE4D0E6DD7

Q34788361-250E57B4-D7F0-499E-866F-BCD50D34A87E

Q34788361-252343C6-6A57-4E5A-AE87-FFF76C9EE0FC

Q34788361-258B512A-0B34-47DE-82BC-4DC8DF5D485B

Q34788361-32B2320F-3186-4AB3-A75F-4CD36B8E2BC4

Q34788361-5259BB67-20FE-4C73-97F8-5DC0531B4A63

Q34788361-83FA893C-04A0-4A13-9898-EB0D4462A2C7

Q34788361-C637B875-5B63-4B7B-8EF8-44E12342AF03

Q34788361-F5E8DD81-D204-4C4E-B2E0-6A46E0FB7781

P2860

Q34788361-04B2A9D0-5DD9-4D4E-AE03-A329F1F548F7

Q34788361-0B2052F7-3C43-4EB5-B750-1EF930AB2051

Q34788361-107AE480-544B-4B2D-A096-716575E442B5

Q34788361-2465388E-80F1-4659-9CB2-4A1CE5FC6607

Q34788361-261714A4-5A84-4366-8D25-25058FB1B5FA

Q34788361-415DF83C-5A3F-423D-BE61-C68218B518C4

Q34788361-508A8DB5-5061-4ECD-811C-D647F1BE77CF

Q34788361-52B73B99-434A-49EC-A0E7-810DF525BD3C

Q34788361-570FFC75-3385-4A10-A384-F35623168B40

Q34788361-65BD0686-5952-4B14-92C9-4413FC0B04CC

P2888

Q34788361-066C5BF7-BC4B-4249-9904-E6C0B6C3D4B6

P304

Q34788361-64EF96C8-6977-4B84-838D-53A011FCF889

P31

Q34788361-0E6743C8-E97A-4DDE-B2DC-07D725959E3A

P356

Q34788361-2254CCFE-BD92-4E1D-8BE0-D111E77F2502

P407

Q34788361-9F02795D-064D-4FC5-BE5B-CE5E53E64B52

P478

Q34788361-292AD7DA-AE53-4A63-B09A-99BCA26787BD

P577

Q34788361-6E43F5F7-6205-47F6-9FCA-65C21722A040

P5875

Q34788361-0CC3A36B-B0BE-4063-958A-77F5FA4F9A46

P6179

Q34788361-687EA32B-81E3-4E41-A0BC-9DB10273A18E

P698

Q34788361-C6DA2689-5D04-4A17-B117-F69798F19BAF

P921

Q34788361-060BEDDA-C796-42D9-93CA-F5AD38EE2A29

P932

Q34788361-EE3EC795-47E7-496E-AE01-36530AC133C7

P356

1471-2407-13-320

P1433

P1476

Anti-lymphangiogenic propertie ...... carcinoma experimental models

@en

P2093

Cherie-Ann O Nathan

http://www.w3.org/2001/XMLSchema#string

Fleurette Abreo

http://www.w3.org/2001/XMLSchema#string

Jonathan Steven Alexander

http://www.w3.org/2001/XMLSchema#string

Kunal Sonavane

http://www.w3.org/2001/XMLSchema#string

Matthew C Raley

http://www.w3.org/2001/XMLSchema#string

Michael A Brodt

http://www.w3.org/2001/XMLSchema#string

Oleksandr Ekshyyan

http://www.w3.org/2001/XMLSchema#string

Tara N Moore-Medlin

http://www.w3.org/2001/XMLSchema#string

Xiaohua Rong

http://www.w3.org/2001/XMLSchema#string

P2860

Current development of mTOR inhibitors as anticancer agents

Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels

mTOR signaling at a glance

Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.

Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.

Soluble VEGFR-2: an antilymphangiogenic variant of VEGF receptors.

Rapamycin inhibits lymphatic endothelial cell tube formation by downregulating vascular endothelial growth factor receptor 3 protein expression.

Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer

The role of the VEGF-C/VEGFR-3 axis in cancer progression.

P2888

1471-2407-13-320

P304

320

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-13-320

http://www.w3.org/2001/XMLSchema#string

P407

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

244480037

http://www.w3.org/2001/XMLSchema#string

P6179

1044015908

http://www.w3.org/2001/XMLSchema#string

P698

23815869

http://www.w3.org/2001/XMLSchema#string

P921

head and neck squamous cell carcinoma

P932

3702388

http://www.w3.org/2001/XMLSchema#string